Relmada Pharmaceutical Issues Amended Lawsuit Against Laidlaw

An amended lawsuit has been filed against British company Laidlaw and Company by pharmaceutical giant Relmada Therapeutics. Also named in the suit are CEO Matthew D. Eitner and Managing Partner James P. Ahern.

Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern

The amended complaint, filed in the U.S. District Court of the District of Nevada, claims a breach of fiduciary duty regarding Relmada when it disclosed confidential company information, according to PRNewswire. Relmada is asking the court to award them damages for the fees were incurred when they were forced to answer false and misleading charges.

The court had previously issued a temporary restraining order against Laidlaw on the same charges of dissemination misleading material. Relmada’s Board of Directors feel that the company should be compensated due to the damage suffered by Laidlaw’s actions.

Stockholders received a letter outlining the actions taken by Relmada. The corrospondence also stated that Shareem Agkargar and Maged Shemouda were voted in overwhelmingly as new directors. Relmada’s board will vigorously pursue the legal action and continue to work toward protecting the company’s interests.

Laidlaw broker, Matthew Eitner, is also under fire for securities and investment fraud. Gallick has over 20 years experience and has been a registered broker with Laidlaw for 7 years.

According to Broker Check, Gallick has seven complaints dating back to 1998. He is the subject of at least 6 lawsuits; some have been settled.

Individuals who may have complaints against Gallick are encouraged to contact the law offices of Fitapelli Kurta. Additional complaints against James Ahern (Laidlaw) are filed as well

Laidlaw and Company has received at least 60 customer complaints. They have also been sanctioned for not properly filing records of the complaints.

Learn more:

Leave a Reply

Your email address will not be published. Required fields are marked *